PMC:7565665 / 70183-71436
Annnotations
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T496 | 810-820 | Disease | denotes | infections | http://purl.obolibrary.org/obo/MONDO_0005550 |
T497 | 1031-1041 | Disease | denotes | infections | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T806 | 54-58 | http://purl.obolibrary.org/obo/PR_000001044 | denotes | CFTR |
T807 | 713-721 | http://purl.obolibrary.org/obo/NCBITaxon_2 | denotes | bacteria |
T808 | 750-751 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T809 | 955-963 | http://purl.obolibrary.org/obo/NCBITaxon_2 | denotes | bacteria |
T810 | 1222-1230 | http://purl.obolibrary.org/obo/NCBITaxon_2 | denotes | bacteria |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T15814 | 177-188 | Chemical | denotes | antibiotics | http://purl.obolibrary.org/obo/CHEBI_33281 |
T63851 | 332-334 | Chemical | denotes | IV | http://purl.obolibrary.org/obo/CHEBI_74327 |
T174 | 336-347 | Chemical | denotes | antibiotics | http://purl.obolibrary.org/obo/CHEBI_33281 |
T66577 | 531-533 | Chemical | denotes | IV | http://purl.obolibrary.org/obo/CHEBI_74327 |
T99338 | 534-545 | Chemical | denotes | antibiotics | http://purl.obolibrary.org/obo/CHEBI_33281 |
T70909 | 628-639 | Chemical | denotes | antibiotics | http://purl.obolibrary.org/obo/CHEBI_33281 |
T83059 | 733-736 | Chemical | denotes | MDR | http://purl.obolibrary.org/obo/CHEBI_53218 |
T72009 | 932-935 | Chemical | denotes | MDR | http://purl.obolibrary.org/obo/CHEBI_53218 |
T3847 | 976-979 | Chemical | denotes | MDR | http://purl.obolibrary.org/obo/CHEBI_53218 |
T45661 | 995-1006 | Chemical | denotes | antibiotics | http://purl.obolibrary.org/obo/CHEBI_33281 |
T7261 | 1062-1073 | Chemical | denotes | antibiotics | http://purl.obolibrary.org/obo/CHEBI_33281 |
T16389 | 1218-1221 | Chemical | denotes | MDR | http://purl.obolibrary.org/obo/CHEBI_53218 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
1734 | 54-58 | Gene | denotes | CFTR | Gene:1080 |
1735 | 230-238 | Species | denotes | patients | Tax:9606 |
1736 | 591-599 | Species | denotes | patients | Tax:9606 |
1737 | 656-663 | Species | denotes | patient | Tax:9606 |
1738 | 671-678 | Species | denotes | patient | Tax:9606 |
1739 | 774-782 | Species | denotes | patients | Tax:9606 |
1740 | 810-820 | Disease | denotes | infections | MESH:D007239 |
1741 | 1031-1041 | Disease | denotes | infections | MESH:D007239 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T927 | 54-58 | http://purl.obolibrary.org/obo/GO_0005260 | denotes | CFTR |
T928 | 59-68 | http://purl.obolibrary.org/obo/GO_0016236 | denotes | autophagy |
T929 | 59-68 | http://purl.obolibrary.org/obo/GO_0006914 | denotes | autophagy |
T930 | 1183-1192 | http://purl.obolibrary.org/obo/GO_0016236 | denotes | autophagy |
T931 | 1183-1192 | http://purl.obolibrary.org/obo/GO_0006914 | denotes | autophagy |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T367 | 0-209 | Sentence | denotes | Another reason to explore treatments that restore the CFTR-autophagy function to treat exacerbations is that the current first-line treatment for exacerbations usually includes antibiotics [4,173,210,212,213]. |
T368 | 210-363 | Sentence | denotes | In situations where patients experience severe exacerbations, they are often hospitalized and given powerful intravenous (IV) antibiotics [4,31,173,176]. |
T369 | 364-457 | Sentence | denotes | This is part of what plays into the exorbitant costs associated with recurrent exacerbations. |
T370 | 458-606 | Sentence | denotes | When looking specifically at exacerbations requiring hospitalization and IV-antibiotics, the cost is USD 36,319 per exacerbation for patients [176]. |
T371 | 607-858 | Sentence | denotes | This frequent use of antibiotics in both the out-patient and in-patient treatment of exacerbations causes bacteria to develop MDR, which poses a significant issue for patients as the treatment of future infections becomes more difficult [151,214,215]. |
T372 | 859-946 | Sentence | denotes | In fact, many pathogens that cause exacerbations have been found to have MDR [214,215]. |
T373 | 947-1105 | Sentence | denotes | As more bacteria demonstrate MDR, more powerful antibiotics are needed to fight off infections, but these powerful antibiotics can have negative side effects. |
T374 | 1106-1253 | Sentence | denotes | As such, researchers have begun investigating the potential of targeting the autophagy pathway to fight off the MDR bacteria causing exacerbations. |